| References |
| 1 |
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
|
| 2 |
Optimization of Mass Spectrometry Imaging for Drug Metabolism and Distribution Studies in the Zebrafish Larvae Model: A Case Study with the Opioid Antagonist Naloxone
|
| 3 |
Metabolism and Disposition of Prescription Opioids: A Review
|
| 4 |
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
|
| 5 |
Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward. J Pharmacol Exp Ther. 2022 Aug;382(2):167-180. doi: 10.1124/jpet.122.001217.
|
| 6 |
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
|
| 7 |
Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery. Ann Transl Med. 2022 Dec;10(23):1262. doi: 10.21037/atm-2022-58.
|
| 8 |
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
|
